Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.


International Consensus Conference to Develop Improvement Criteria for Juvenile Dermatomyositis and Adult Dermatomyositis and Polymyositis: Workshop to Define Minimal Clinical Improvement and Major Clinical Response

Monday, June 09, 2014 - Tuesday, June 10, 2014
Hotel Novotel La Defense, Paris, France

Anticipated goals and use of results: We anticipate developing composite endpoints for future clinical trials that will be fully validated, endorsed by the ACR and EULAR, and used by all forthcoming myositis clinical trials and clinical studies as clinical endpoints. A likely secondary outcome of this work would be the stimulus to develop new therapies for myositis and conduct clinical trials of new therapeutic agents in myositis patients, given adequate ways to assess efficacy of new therapies in trials.

Dr. Sheila Newton (919) 541-4343

Co-funding Institute(s):
National Institute of Environmental Health Sciences
Office of Rare Diseases Research

From the National Center for Advancing Translational Sciences

From the National Institutes of Health

Connect with ORDR

See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.